Edition:
United States

Dr.Reddy's Laboratories Ltd (RDY.N)

RDY.N on New York Stock Exchange

43.51USD
12:45pm EDT
Change (% chg)

$-0.10 (-0.23%)
Prev Close
$43.61
Open
$43.55
Day's High
$43.85
Day's Low
$43.43
Volume
38,149
Avg. Vol
98,631
52-wk High
$68.00
52-wk Low
$40.74

RDY.N

Chart for RDY.N

About

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)

Overall

Beta: 0.87
Market Cap(Mil.): $7,526.71
Shares Outstanding(Mil.): 170.54
Dividend: 0.30
Yield (%): 0.68

Financials

  RDY.N Industry Sector
P/E (TTM): 33.26 39.19 39.69
EPS (TTM): 1.31 -- --
ROI: -- 15.23 14.44
ROE: -- 16.16 15.49

India's Dr Reddy's in $350 million deal to buy eight U.S. drugs from Teva, Allergan

MUMBAI India's second-largest drugmaker Dr Reddy's Laboratories Ltd said it agreed to buy eight generic drugs from Teva Pharmaceutical Industries and Allergan Plc for $350 million in cash to bolster its U.S. business.

Jun 11 2016

BRIEF-Spectrum Pharma says Dr Reddy's will be permitted to market generic version of Folotyn in US on Dec 1, 2022 or earlier

* Co's unit, dr. Reddy's labs, ltd entered into settlement agreement to resolve their patent litigation relating to folotyn

May 31 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Wright Reports
$75.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.